(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -8.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.22%.
Nektar Therapeutics's revenue in 2026 is $54,589,000.On average, 13 Wall Street analysts forecast NKTR's revenue for 2026 to be $1,505,125,605, with the lowest NKTR revenue forecast at $1,405,325,633, and the highest NKTR revenue forecast at $1,604,823,147. On average, 13 Wall Street analysts forecast NKTR's revenue for 2027 to be $1,288,249,307, with the lowest NKTR revenue forecast at $271,027,086, and the highest NKTR revenue forecast at $1,636,917,561.
In 2028, NKTR is forecast to generate $1,516,904,937 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,289,384,336.